CD70 and non-Hodgkin lymphoma: Due to the constitutive expression of CD70 on solid tumors and B-cell lymphomas, several CD70-targeting molecules including antibodies and ADCs have recently entered preclinical and clinical testing in NHL and renal cell cancer [24, 30, 38].